The Phase I trial of lenalidomide in patients with high-risk AML or MDS post-allogeneic bone marrow transplantation aims to evaluate the drug's efficacy in preventing leukemia relapse. Given the high unmet medical need in this patient population, successful outcomes could position lenalidomide as a key maintenance therapy, potentially expanding its market share beyond current indications. The collaboration with Celgene, a significant player in hematology, enhances the asset's commercial viability. However, the competitive landscape includes other therapies targeting AML and MDS, necessitating a thorough assessment of lenalidomide's unique value proposition and safety profile in this specific setting.